IL133070A0 - Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses - Google Patents

Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses

Info

Publication number
IL133070A0
IL133070A0 IL13307098A IL13307098A IL133070A0 IL 133070 A0 IL133070 A0 IL 133070A0 IL 13307098 A IL13307098 A IL 13307098A IL 13307098 A IL13307098 A IL 13307098A IL 133070 A0 IL133070 A0 IL 133070A0
Authority
IL
Israel
Prior art keywords
adaptive
counter
composition
immune responses
graft rejection
Prior art date
Application number
IL13307098A
Original Assignee
Us Navy
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Navy, Wisconsin Alumni Res Found filed Critical Us Navy
Publication of IL133070A0 publication Critical patent/IL133070A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
IL13307098A 1997-06-11 1998-06-10 Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses IL133070A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4938997P 1997-06-11 1997-06-11
PCT/US1998/011910 WO1998056417A1 (en) 1997-06-11 1998-06-10 Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses

Publications (1)

Publication Number Publication Date
IL133070A0 true IL133070A0 (en) 2001-03-19

Family

ID=21959563

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13307098A IL133070A0 (en) 1997-06-11 1998-06-10 Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses

Country Status (6)

Country Link
EP (1) EP1009432A4 (en)
JP (1) JP2002504120A (en)
AU (1) AU748533B2 (en)
CA (1) CA2291338A1 (en)
IL (1) IL133070A0 (en)
WO (1) WO1998056417A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
AU2215700A (en) * 1998-12-29 2000-07-31 University Of Vermont And State Agricultural College, The Use of cd40 engagement to alter t cell receptor usage
DE60034428T2 (en) * 1999-01-08 2008-01-03 Wisconsin Alumni Research Foundation, Madison PREVENTING CRANICAL TRANSPLANT EXHAUST WITH A COMBINATION OF IMMUNOXINS AND COSTIMULATION BLOCKERS
AU2001233027A1 (en) * 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
CN1441675A (en) 2000-05-12 2003-09-10 贝斯以色列护理医疗中心有限公司 Compositions and methods for achieving immune suppression
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
AU7541101A (en) 2000-06-09 2001-12-24 Bristol Myers Squibb Co Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion
AU2001273174B2 (en) 2000-07-03 2006-05-18 Bristol-Myers Squibb Company Methods for treating rheumatic diseases using a soluble CTLA4 molecule
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
WO2002060485A2 (en) * 2001-01-31 2002-08-08 Idec Pharmaceuticals Corporation Use of immunoregulatory antibodies in the treatment of neoplastic disorders
US20050101012A1 (en) 2001-03-12 2005-05-12 Gerold Schuler CD4+CD25+ regulatory T cells from human blood
EP1241249A1 (en) * 2001-03-12 2002-09-18 Gerold Schuler CD4+CD25+regulatory T cells from human blood
AU2002305716B2 (en) 2001-05-23 2007-10-25 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
US8222033B2 (en) 2002-08-12 2012-07-17 Argos Therapeutics, Inc. CD4+CD25− T cells and Tr1-like regulatory T cells
GB0815788D0 (en) * 2008-08-29 2008-10-08 Isis Innovation Therapeutic antibodies
KR20210024048A (en) 2018-06-22 2021-03-04 가부시키가이샤 준텐 바이오 Antibodies and induced lymphocytes that induce immune tolerance, using a mixture of cells having a complex state, and cell therapy and therapy using induced lymphocytes
WO2019245039A1 (en) 2018-06-22 2019-12-26 株式会社Ｊｕｎｔｅｎ Ｂｉｏ Composition for eliciting infectious immunological tolerance
MX2020014101A (en) 2018-06-22 2021-05-27 Junten Bio Co Ltd Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte.
WO2023153388A1 (en) * 2022-02-08 2023-08-17 学校法人順天堂 Allotransplantation method and rejection rpeventing method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0784482A2 (en) * 1994-06-07 1997-07-23 The Regents Of The University Of Minnesota Methods for inhibiting antigen specific t cell responses
WO1997034633A1 (en) * 1996-03-20 1997-09-25 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith

Also Published As

Publication number Publication date
EP1009432A4 (en) 2004-07-07
CA2291338A1 (en) 1998-12-17
JP2002504120A (en) 2002-02-05
EP1009432A1 (en) 2000-06-21
WO1998056417A1 (en) 1998-12-17
AU748533B2 (en) 2002-06-06
AU7956798A (en) 1998-12-30

Similar Documents

Publication Publication Date Title
IL133070A0 (en) Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses
IL118589A0 (en) Compositions and method for improving autologous fat grafting
IL115551A0 (en) Intraluminal graft and method for insertion thereof
GB2288257B (en) Improved nutritional micromcomputer and method
AR244539A1 (en) Tissue graft composition and method
HUP0000302A3 (en) Ob fusion protein compositions and methods
ZA964733B (en) Ob protein compositions and methods
ZA958028B (en) Compositions and methods for treatig mast-cell mediated conditions
AU6237596A (en) Angiosurgical device and vascular graft and vascular annulusfor vessel-vascular graft binding
PL321935A1 (en) Electroplating compositions and methods
GB2298713B (en) Method and composition
EP0555413A4 (en) Methods and compositions for suppressing allograft rejection in mammals
ZA989398B (en) Method and composition (l)
GB9624501D0 (en) Insecticial compositions and method
EP0873071A4 (en) Organizer rack component and method of using same
GB2318356B (en) Composition and method
GB9508546D0 (en) Method and composition
GB9414888D0 (en) Method and composition
GB9419087D0 (en) Method and composition
AU6648498A (en) Methods and compositions using interleukin-13 for enhancing immune responses
GB9026896D0 (en) Method and composition
GB9619261D0 (en) Pesticidal composition and method
GB9601656D0 (en) Novel composition and method
ZA946995B (en) Specimens and their making methods
ZA919566B (en) Jumper switch means and method